Sesh wins SDSU San Diego Angel Conference, secures $200K to advance precision oncology blood test
What's the deal? SeshDealroom has a profile for this one. Try Dealroom → Incorporated, a San Diego-based precision immuno-oncology startup, has won the 2026 SDSU San Diego Angel ConferenceDealroom has a profile for this one. Try Dealroom → and secured a $200,000 investment to commercialise its blood-based liquid biopsy technology.
The company, led by founder and chief executive officer Andrew Sinkoe, is developing a blood test that detects predictive cancer biomarkers from a simple blood draw. The goal: help clinicians choose the right individualised treatment for each patient.
Two other finalists — My Village Innovations and Vayim — each received $35,000 investments. Sesh was selected from a group that also included Shezza, PolyVascular, and Cytodyme.
Why now? Liquid biopsy — a method of analysing blood samples for cancer markers instead of relying on invasive tissue biopsies — has gained significant traction in oncology. Sesh's approach focuses specifically on predicting which therapies will work best for individual patients, an area of growing clinical demand.
The company has already drawn support from the National Cancer InstituteDealroom has a profile for this one. Try Dealroom →, EvoNexusDealroom has a profile for this one. Try Dealroom →, and Connect, reflecting San Diego's strength as a life sciences hub. The SDAC fund will continue accepting additional investments in Sesh throughout June.
What could go wrong? Commercialising diagnostic blood tests is a long, expensive road. Sesh still needs to navigate regulatory approvals, clinical validation, and competition from well-funded liquid biopsy players. A $200,000 angel investment is a meaningful signal of confidence, but it's a fraction of what the company will likely need to reach market.
The signal: The liquid biopsy market has attracted billions in venture funding in recent years, but most of that capital has flowed to later-stage players focused on early cancer detection rather than treatment selection. Sesh's focus on predictive biomarkers — guiding therapy decisions, not just diagnosis — positions it in a less crowded but clinically critical niche, one where angel-stage backing from funds like the San Diego Angel Conference can provide an early foothold before larger life sciences investors enter the picture.
Read more: Connect
